Ipsen Bets on Viral Infection in Kidney Transplantation, Buying BK Virus Antibody in €700 Million Deal

The success of kidney transplantation depends not only on surgery and immunosuppression, but also on viruses in the patient’s body that are usually silent and become active again after immunity is lowered. French pharmaceutical company Ipsen announced on July 1 that it will acquire Swiss biotech company Memo Therapeutics, whose core asset is potravitug, a monoclonal antibody targeting BK polyomavirus. Including subsequent milestone payments, the total transaction value could exceed €700 million.

Under the agreement, Memo shareholders will receive €200 million in cash at closing, followed by deferred payments tied to development, approval, and sales milestones. Ipsen expects the transaction to close in the third quarter of 2026, subject to customary closing conditions. Memo’s assets and employees unrelated to potravitug will be transferred before closing into a newly established company, Memorises Bio, to be retained by the existing shareholders.

potravitug targets BK polyomavirus-associated nephropathy. BK virus is very common, and most people are exposed during childhood, usually without problems. But kidney transplant patients need to take anti-rejection drugs over the long term. Once immune defenses are lowered, the virus may begin replicating again, further damaging the transplanted kidney and, in severe cases, leading to graft loss, a return to dialysis, or the need for another transplant.

There are currently no approved targeted therapies in this field, and clinical management often can only reduce the intensity of immunosuppression in exchange for lowering viral load. That approach carries its own cost: as immunity is restored, the risk of rejection may also rise. In acquiring potravitug, Ipsen is focusing precisely on the possibility that, if it can block viral entry into host cells, it may reduce this dilemma.

potravitug is a monoclonal antibody against the BK virus VP1 capsid protein, designed to prevent the virus from attaching to and entering cells. Ipsen said the Phase 2 SAFE KIDNEY II trial enrolled 95 kidney transplant patients across 22 centers in the United States, making it the largest placebo-controlled study in this population. The company said the overall data support launching the pivotal Phase 2/3 SAFE KIDNEY III trial later in 2026.

Public data show that the potravitug group outperformed placebo in reductions in viral load and improvements in kidney histology. By week 38, BK virus DNAemia fell to undetectable levels in 24.4% of patients in the treatment group, compared with 13.0% in the placebo group; viral load reductions of more than 2 log10 occurred in 40.3% and 24.7%, respectively. By week 20, the proportion of patients in the treatment group with biopsy-confirmed BK virus-associated nephropathy fell from 51.2% to 31.6%, while no change was seen in the placebo group. Ipsen also said no treatment-related serious adverse events were reported in the trial.

**Background Context**

This deal continues the path of large pharmaceutical companies using acquisitions to strengthen mid- to late-stage pipelines, but the target differs from common oncology assets and instead addresses a clinical need at the intersection of post-transplant infection and rare disease. potravitug received Fast Track designation from the U.S. FDA in May 2023 and orphan drug designation in the European Union in December 2025. However, the current data still come from a Phase 2 study of limited size. Whether it can truly change graft survival and reduce the risks of rejection and retransplantation will depend on whether subsequent pivotal trials can confirm efficacy and safety in a larger population.